Article Information
History
- February 17, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Marcelo Boareto1,*,
- Yumi Yamamoto1,
- Jeffrey D. Long2,5,
- Cristina Sampaio3,
- Peter McColgan4,
- Cheikh Diack1,& and
- Patricia Sanwald Ducray1,&
- 1Roche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd. Grenzacherstrasse 124, 4070 Basel, Switzerland
- 2Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
- 3Clinical Department, CHDI Management/CHDI Foundation, Princeton, New Jersey, USA
- 4Roche Pharmaceutical Research and Early, Roche Innovation Center Welwyn, Welwyn Garden City, UK
- 5Department of Biostatistics, University of Iowa, Iowa City USA
- ↵*corresponding author email address: marcelo.boareto{at}roche.com,
Posted February 17, 2024.
Modeling disease progression and placebo response in Huntington’s Disease: Insights from Enroll-HD and GENERATION HD1 cohorts
